Overcoming Immunotherapy Resistance in Metastatic Gastric/Esophageal Cancer
Official title: Overcoming Immunotherapy Resistance in Patients with Metastatic Gastric/Esophageal Adenocarcinoma
Funded at Mayo Clinic Rochester · NIH-11448895 · Data updated 2026-11-12
A Mayo Clinic-led study aims to find better combos of immune therapy and standard treatment to help people with metastatic gastric and esophageal cancer who don’t respond well to current options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | January 1, 2021 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $748,291 |
| NIH project number | 2R01CA248147-06 |
| Project ID | NIH-11448895 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with metastatic gastroesophageal adenocarcinoma who are candidates for immune therapy and chemotherapy.
✕Less likely to help
Patients whose tumors do not rely on pathways targeted by the proposed therapy or who cannot tolerate the combination may not benefit.
What this research studies
This project looks at why metastatic gastroesophageal adenocarcinoma becomes resistant to immune checkpoint inhibitors combined with chemotherapy. Researchers will explore how tumors change their blood vessels and immune environment, then test a Phase 2 treatment plan that combines an immune drug, anti-angiogenesis therapy, and chemotherapy. They will examine tissue samples to map the tumor microenvironment and identify clues that predict who might benefit. The goal is to develop new, more effective immune-based treatment strategies for this difficult cancer.
Why it matters
Potential benefit: If successful, patients may have more effective treatment options that overcome resistance to current therapies.
How similar studies have gone: Preliminary data suggest that combining immune therapy with anti-angiogenesis approaches can overcome resistance in some cancers, but results for GE cancer are still emerging.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Yoon, Harry H — Mayo Clinic Rochester
- Study coordinator: Yoon, Harry H
Related research
Other NIH-funded projects on the same topics.
-
Natural products to block IL-8 signaling and prevent Barrett's Esophagus from turning into esophageal cancer
A搜索-friendly plan to use safe natural compounds to interrupt a key inflammatory signal (IL-8) and stop Barrett’s esophagus from turning into esophageal cancer in people with GERD.
-
NEK2's role in esophageal cancer development
A study looking at how the NEK2 protein contributes to the development and progression of esophageal adenocarcinoma in conditions like Barrett’s esophagus.
-
In vivo B7-H3 CAR-T cells for pancreatic cancer therapy
A patient-friendly look at a new approach that aims to produce CAR-T cells directly inside the body to target pancreatic cancer.
-
Novel combo therapy using oncolytic adenovirus and immune drugs for pancreatic cancer
Aims to combine an oncolytic virus with immune therapies to help shrink pancreatic tumors before surgery and keep them from coming back.
-
Understanding why some esophageal cancer patients don’t respond to chemoradiation
A research project at MD Anderson is looking at why esophageal cancer patients often don’t fully respond to chemoradiation and how tumor biology and the surrounding environment affect treatment.
-
AI-powered screening to detect Barrett’s esophagus and early esophageal cancer
A Mayo Clinic team is testing an AI-assisted tool that uses health data to identify people at risk for Barrett’s esophagus and early esophageal cancer so they can get timely endoscopic evaluation.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.